Veeva Vault Safety sits in the enterprise tier of the pharmacovigilance market, and for organisations already standardised on the Veeva Vault ecosystem it has an obvious structural advantage: safety data lives alongside clinical, regulatory, and quality content on one vendor's platform. That is a genuinely good reason to choose it, and if it describes your organisation this guide will probably confirm you are on the right track.
But the same integrated-suite logic is what makes it a poor fit for other teams. A CRO processing cases for a dozen sponsors, or a small-to-mid pharma company with one product and no IT function, is buying enterprise scope it will not use — and paying the enterprise implementation and licensing profile that comes with it. This guide is for those teams.
How we handle competitor claims on this page
We do not publish feature-by-feature tick tables for other vendors. Safety platforms ship changes continuously, and only the vendor can confirm what their product does today — so a table claiming a named product 'lacks' a capability would be unreliable the month after we wrote it. What follows instead: factual statements about PVgenix, broad category positioning for the enterprise tier, and a list of questions to ask every vendor on your shortlist, including us. Verify anything that will drive your decision directly with the vendor.
The reasons are consistent across the CROs and small-to-mid pharma teams we speak to, and none of them are about capability gaps in the enterprise products. They are about fit.
- Cost profile — enterprise licensing is sized for organisations with large case volumes and large teams; below a certain scale the cost per case becomes hard to justify to a finance director
- Implementation timeline — enterprise deployments are typically measured in months of configuration and qualification before the first case is processed, which does not fit a CRO that just won a sponsor contract
- Scope you will not use — if you do not run clinical trials, regulatory submissions, and quality content on the same suite, the integrated ecosystem advantage does not apply to you
- Per-tenant economics for CROs — a CRO needs to onboard a new sponsor without a new implementation project each time
- Internal capacity — some teams simply do not have the QA, CSV, or IT capacity that an enterprise rollout assumes
The market divides into three practical groups, and knowing which group you are shopping in saves a lot of wasted demo time.
| Group | Examples | Typically suits |
|---|---|---|
| Legacy enterprise safety systems | Oracle Argus Safety | Large marketing authorisation holders with established estates, deep integrations, and in-house teams to run them |
| Enterprise cloud suites | Veeva Vault Safety, ArisGlobal LifeSphere Safety | Organisations standardising multiple functions on one vendor's cloud platform, with the budget and internal capacity for an enterprise rollout |
| Modern cloud-native PV platforms | PVgenix and similar | CROs, small-to-mid pharma, biotech, and generics that need full ICSR lifecycle coverage on a lower cost base and a faster setup |
If you are reading a page about Vault Safety alternatives, you are most likely deciding between staying in group two or moving to group three. The question is not which product has more features — it is whether the features you actually use justify the cost and implementation model attached to them.
Everything in this section is a factual statement about PVgenix, sourced from our own platform documentation. Compare it against what the vendor on the other side of your evaluation tells you about theirs.
| Dimension | PVgenix |
|---|---|
| ICSR lifecycle coverage | Intake, triage, data entry, coding, assessment, quality and medical review, and submission on one connected case record |
| Multi-channel intake | Email, messaging and social channels, web reporter portal, file-based and API intake, configurable per tenant |
| AI assistance | Extraction from unstructured sources, MedDRA coding proposals, narrative drafting, and literature screening — all confidence-scored with a mandatory human review gate |
| Coding | MedDRA and WHO Drug Dictionary with admin-controlled version management, auto-coding, and recorded manual override (dictionaries licensed by the client) |
| Regulatory submission | E2B(R2) and E2B(R3) generation, CIOMS I and MedWatch 3500A outputs, regulatory clock and configurable rules engine, ACK reconciliation |
| Gateway | AS2 gateway built into the platform — no separate gateway product to license or qualify |
| Surveillance | Literature monitoring with AI-assisted screening, and signal detection using PRR, ROR, BCPNN/IC, and EBGM with masking detection |
| Aggregate reporting | DSUR, PBRER/PSUR, and PADER support with line listings and summary tabulations from one interval query at data lock |
| Quality management | Integrated CAPA, deviation, and change-control tracking tied to case processing |
| Deployment | Multi-tenant SaaS or dedicated single-tenant, both from the same codebase; EU, US, and India region hosting options |
| Provisioning timeline | Initial SaaS platform build about three days plus three days of setup documentation; each new tenant thereafter self-provisioned from the portal. IT setup and documentation handover only — not your qualification effort |
| Compliance alignment | Designed around 21 CFR Part 11, EU GVP, GAMP 5, and GxP, with RBAC, tenant isolation, e-signatures, and tamper-evident audit logging |
| Documentation set | VMP, URS, FS, DS, IQ/OQ/PQ, RTM, and SOP templates provided to support client-led qualification |
| Pricing | Quoted per engagement — contact us |
Validation is environment-specific
PVgenix is validation-ready and audit-ready: it ships with a complete IQ/OQ/PQ documentation package to support client-led validation. 'Validated' is a state achieved only after qualification is executed in a specific client environment.
A comparison page that concludes the author's product wins every scenario is not a comparison. Here are the situations where we would tell you to stay with an enterprise suite.
- You are already standardised on one vendor's cloud suite for clinical, regulatory, and quality, and the value you are buying is that content and data sit in one ecosystem — that integration advantage is real and we do not replicate it
- You are a large marketing authorisation holder with a mature safety estate, deep custom integrations, and an internal team that already runs it well — the migration cost is unlikely to pay back
- You need a specific niche module or regional submission route that sits outside the capability set described above; ask us directly rather than assuming, but the honest answer is sometimes no
- Your procurement process requires a vendor of a particular size, public-company status, or analyst-report placement
- You want the vendor to run your pharmacovigilance operations — we are a software provider, not a PV service provider or consultancy
Rather than trusting anyone's comparison table — including ours — put the same questions to each vendor and compare the answers you get in writing. These are the ones that surface real cost and real timeline.
| Ask | Why it matters |
|---|---|
| What is the total first-year cost, including implementation, qualification support, and hosting? | Licence cost alone routinely understates first-year spend by a wide margin |
| Is an AS2 gateway included, or is it a separately licensed product? | A separate gateway adds licence cost and another component in your qualification scope |
| How long from contract signature to our first live submission? | Separates IT provisioning time from the full path to operational go-live |
| What exactly do you deliver for validation, and what do we own? | The line between 'validation-ready documentation' and executed qualification is where projects overrun |
| For CROs: what does onboarding sponsor number two cost and take? | Per-tenant economics decide whether the platform scales with your business |
| Are MedDRA and WHO-DD licences included? | Dictionary licences are almost always the client's responsibility — confirm it rather than assume |
| Where is our data hosted, and can we choose the region? | Sponsor contracts and GDPR frequently dictate residency |
| How do we get our data out, in what format, if we leave? | E2B export should be a standard capability, not a professional-services engagement |
| Which AI steps are automated, and where is the human review gate? | You need to know exactly where accountability sits before an inspection asks |
| Can we see the audit trail for a case, in the demo, on real screens? | Audit-trail depth is easy to claim in a slide and hard to fake in a live system |
Migration is the single biggest source of hesitation, and reasonably so. The vendor-neutral path is E2B transfer: export cases as E2B XML from the incumbent system and import them into the new platform. That handles the structured case data well. What it does not carry cleanly is everything around the case — attachments, audit history, workflow state, and any custom fields — which is where field mapping and reconciliation work is required. PVgenix supports migration via E2B transfer plus data migration tooling for legacy extraction, field mapping, and reconciliation; scope is agreed per engagement.
The decision in one line
If the integrated-suite advantage is the thing you are actually buying, stay in the enterprise tier. If you are paying for enterprise scope you do not use, a modern cloud-native platform delivers the same core ICSR capability on a materially lower cost base and a much shorter setup.
For the economics behind that conclusion, our guide on pharmacovigilance software cost breaks down where the money actually goes, and Oracle Argus alternatives covers the same evaluation from the legacy-enterprise starting point. If you want to see the capability set rather than read about it, the pharmacovigilance software overview is the place to start.
Frequently asked questions
Common questions
Alternatives fall into three groups: legacy enterprise safety systems such as Oracle Argus Safety; other enterprise cloud suites such as ArisGlobal LifeSphere Safety; and modern cloud-native pharmacovigilance platforms such as PVgenix, which target CROs and small-to-mid pharma with lower cost and faster provisioning. Which group fits depends less on feature counts than on your scale, your internal IT and QA capacity, and whether you need a single-vendor suite across clinical, regulatory, and quality.
PVgenix covers the full ICSR lifecycle — multi-channel intake, AI-assisted extraction and coding, assessment, E2B(R2)/E2B(R3) submission through a built-in AS2 gateway, literature monitoring, signal detection, aggregate reporting, and QMS — as multi-tenant SaaS or a dedicated single-tenant deployment, provisioned in days rather than months and priced for CROs and small-to-mid pharma. What we do not offer is a single-vendor suite spanning clinical, regulatory, and quality content; if that ecosystem integration is the value you are buying, an enterprise cloud suite is the better fit. For current details of any competitor product, confirm with that vendor directly.
Cost and compliance are independent variables. A credible modern platform is designed around 21 CFR Part 11, EU GVP, GAMP 5, and GxP, with role-based access control, electronic signatures, tamper-evident audit logging, and a complete IQ/OQ/PQ documentation package to support client-led qualification. What lower cost reflects is a modern architecture and an efficient hosting model, not reduced controls. Compliance in practice is always environment-specific and qualification is executed against your environment and SOPs.
Yes. The vendor-neutral route is E2B transfer — exporting cases as E2B XML and importing them into the new system — supplemented by field mapping and reconciliation for attachments, audit history, workflow state, and custom fields that a standard E2B transfer does not carry. Confirm your export rights and formats with your incumbent vendor before you plan a migration.
Separate two timelines. IT provisioning can be fast: a PVgenix SaaS platform build takes about three days plus three days of setup documentation, and subsequent tenants are self-provisioned. The longer timeline is yours — qualification execution, SOP updates, UAT, data migration, and training before operational go-live. Any vendor quoting a single number for the whole switch is describing only their part of it.